Firibastat is an investigational drug.
There have been 5 clinical trials for Firibastat.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 25th 2020.
The most common disease conditions in clinical trials are Hypertension, Ventricular Dysfunction, and Myocardial Infarction. The leading clinical trial sponsors are Quantum Genomics SA, Quotient Sciences, and Eurofins Optimed.
There are three US patents protecting this investigational drug and fifty-six international patents.